Personalis SHERPA, NEOPS
Personalis has launched its Systemic HLA Epitope Ranking Pan Algorithm (SHERPA) machine learning-based tool for identifying and characterizing cancer neoantigens, as well as its Neoantigen Presentation Score (NEOPS) for predicting cancer immunotherapy response.
SHERPA assesses the potential MHC-binding affinity and stability of identified peptides, and incorporates features linked to antigen processing machinery and RNA abundance to produce a presentation rank for each detected peptide. The rank determines the relative likelihood of a given neoantigen being presented and undergoing immunosurveillance. Integrated into the firm's NeXT platform, the tool allows for the development of new neoantigen-based diagnostic biomarkers, such as its NEOPS biomarker, and neoantigen-targeting personalized cancer therapies.
Personalis' NEOPS combines the tumor genomic and immune-related analytics of the firm's NeXT platform to create a composite biomarker, that the firm believes can be more effective in predicting immunotherapy responses than other biomarkers.
NEOPS and SHERPA are the latest updates to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform for biopharmaceutical customers, the company said.
Autogen NeXTRACT 48
AutoGen has launched the NeXTRACT 48 platform for the rapid extraction of viral DNA and/or RNA from a variety of samples including viral transport media, universal viral transport, and sputum. NeXTRACT 48 is compatible with most COVID-19 real-time PCRs diagnostic kits, is compact and easily fits into a BSL2 environment, and can process 48 samples in 20 minutes or 800 samples or more per day, AutoGen said. The platform is ideal for labs looking to supplement COVID-19 viral RNA extractions or to add a back-up platform with a low capital investment and operating cost, with consumables costing less than $5 per sample, the Holliston, Massachusetts-based company said.
Celemics CRV Panel
Celemics has launched its CRV Panel, a multiplexed, target enrichment panel for next-generation sequencing-based identification of common human respiratory viruses, including SARS-CoV-2. The research-use-only assay detects a total of 39 strains of nine viruses including coronaviruses, rhinoviruses, influenzas, and respiratory syncytial viruses. The panel is bundled with non-cloud-based bioinformatics software that enables a complete workflow. The product is available in the US, Europe, Latin America, the Middle East, Singapore, Malaysia, and Thailand via Celemics' certified retailers.
For more new products and services, please visit the New Products page on our website.